GIPR: IHC Expression in Cancer and Radioligand Target Profile
GIPR, gastric inhibitory polypeptide receptor, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, GIPR staining is highest in thyroid cancer (100% of samples positive), prostate cancer (100% of samples positive) and breast cancer (92% of samples positive). Published literature suggests GIPR does not readily internalize, so radionuclide retention may rely on surface binding. Clinical status: FDA-approved drug (any modality).
Is GIPR the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze GIPR freeIs GIPR a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in thyroid cancer, 100% of samples positive.
- ❌ Internalization: Reported not to internalize.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GIPR IHC staining by cancer type
Protein expression of GIPR across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Thyroid Cancer | 0.78 | High | 100% |
| Prostate Cancer | 0.58 | High | 100% |
| Breast Cancer | 0.53 | High | 92% |
| Neuroendocrine Tumors | 0.50 | Medium | 75% |
| Kidney Cancer | 0.42 | Medium | 75% |
| Endometrial Cancer | 0.39 | Medium | 73% |
| Liver Cancer | 0.33 | Medium | 58% |
| Head and Neck Cancer | 0.25 | Medium | 50% |
| Melanoma | 0.24 | Medium | 46% |
| Glioma | 0.21 | Medium | 46% |
| Colorectal Cancer | 0.17 | Low | 42% |
| Lung Cancer | 0.12 | Low | 27% |
| Ovarian Cancer | 0.11 | Low | 25% |
| Gastric Cancer | 0.11 | Low | 17% |
| Testicular Cancer | 0.09 | Low | 27% |
| Bladder Cancer | 0.09 | Low | 18% |
| Pancreatic Cancer | 0.06 | Low | 18% |
| Cervical Cancer | 0.04 | Low | 11% |
| Skin Cancer | 0.03 | Low | 9% |
Not detected by IHC in: lymphoma.
Is GIPR internalized?
No. In cell-based assays, CT-388 activated GLP-1R and GIPR with both having minimal receptor internalization vs their native ligands.
Sources: PMID 41319798 · PMID 40909605 · PMID 40831316 · PMID 40806371 · PMID 40503712. AI-extracted from abstracts, so verify before citing.
GIPR clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for GIPR yet. Search ClinicalTrials.gov for GIPR trials.
GIPR normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GIPR in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GIPR gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.02 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related thyroid cancer radioligand targets
c-MET (MET) · HER3 (ERBB3) · SSTR2 · EPCAM · EGFR · ITGAV · STEAP2 · FAP
See all radioligand therapy targets in thyroid cancer.
See how GIPR ranks against 15,000 targets for your indication.
Analyze GIPR freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.